Last 42.00 GBp
Change Today 0.00 / 0.00%
Volume 0.0
CRX On Other Exchanges
Symbol
Exchange
London
As of 2:50 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

cyprotex plc (CRX) Snapshot

Open
42.00 GBp
Previous Close
42.00 GBp
Day High
42.00 GBp
Day Low
42.00 GBp
52 Week High
01/21/14 - 130.00 GBp
52 Week Low
11/14/14 - 33.50 GBp
Market Cap
9.4M
Average Volume 10 Days
88.3K
EPS TTM
-0.07 GBp
Shares Outstanding
22.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYPROTEX PLC (CRX)

Related News

No related news articles were found.

cyprotex plc (CRX) Related Businessweek News

No Related Businessweek News Found

cyprotex plc (CRX) Details

Cyprotex PLC, together with its subsidiaries, provides in vitro and in silico absorption, distribution, metabolism, excretion, toxicity, and pharmacokinetics (ADMET and PK) services in North America, Mainland Europe, and the United Kingdom. Its ADME and PK services include in vitro metabolism, in vitro permeability, physicochemical properties, bioanalysis, protein binding, and prodrug services; and toxicology services comprise multiparametric toxicity, cardiotoxicity, customised toxicology services, 3D microtissue hepatotoxicity services, mechanistic toxicity services, in vitro drug-drug interaction assays, and genotoxicity assays. The company also provides Cloe PK, a software system that uses physiologically based pharmacokinetic in silico modeling for pharmacokinetic simulation; Cloe HIA, a physiological model for the prediction of human intestinal absorption; Cyprotex Discovery Bus, a software platform to enhance drug discovery; and various in vitro safety testing services for pharmaceutical companies developing topical therapeutics, and for the cosmetics and consumer-products industries. In addition, it offers integrated drug discovery services comprising medicinal chemistry, synthetic chemistry, computational chemistry, bioscience, arrays and libraries, and process and scale-up chemistry; and physicochemical profiling services for measurement of pKa, logP/logD, solubility, and dissolution in aqueous, solvent, biorelevant media, and in the presence of formulation additives. Cyprotex PLC has collaboration with Sygnature Discovery Limited, Sirius Analytical Limited, and Pfizer. It serves various industries, including pharmaceutical, biotechnology, cosmetic, personal care, agrochemical, chemical industries, and academia. The company was founded in 1999 and is headquartered in Macclesfield, the United Kingdom.

112 Employees
Last Reported Date: 08/28/14
Founded in 1999

cyprotex plc (CRX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 229.0K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 136.7K GBP
Compensation as of Fiscal Year 2013.

cyprotex plc (CRX) Key Developments

Cyprotex PLC Enhances SenCeeTox Technology for Prediction of in Vitro Skin Sensitisation

Cyprotex PLC announced significant advances in its SenCeeTox model for the prediction of in vitro skin sensitisation. SenCeeTox, originally developed by CeeTox in Kalamazoo, was acquired by Cyprotex when it purchased the business and assets of CeeTox Inc. in January 2014. SenCeeTox is an in vitro model which assesses multiple endpoints to determine general cytotoxicity, binding of reactive compounds (one of the initial steps in skin sensitisation) and regulation of genes involved in skin sensitisation. Cyprotex has utilised its internal expertise in skin sensitisation and predictive modeling to significantly improve the predictivity of the SenCeeTox model over the currently available in vitro approaches. Furthermore, it is one of the only in vitro models on the market which can accurately predict skin sensitisation potency for categorising into non/minimal, moderate, strong and extreme sensitisers in both 2D and 3D cellular systems. Within the EU, there has been a complete ban on animal testing of cosmetics and personal care ingredients and finished products. This has placed a much greater emphasis on developing alternative in vitro methods. The majority of cosmetic and personal care products are applied topically to the skin, and therefore skin sensitisation is a critical part of the testing strategy before a product reaches the market. Regulatory guidelines have been drafted for two in vitro skin sensitisation methods, the Direct Peptide Reactivity Assay (known as DPRA) and KeratinoSensTM, both of which are offered as services by Cyprotex. However, these single endpoint assays only define individual mechanisms and do not categorise skin sensitisation potency. For this reason, the regulatory authorities recommend a tiered testing strategy using multiple mechanistic endpoints. SenCeeTox® addresses these concerns by monitoring multiple endpoints from a single incubation, by providing potency categorisation and exceeding the predictive capability of both DPRA and KeratinoSensTM. An additional advantage of SenCeeTox® is that it can be used either within a 2D cell-based model or in a 3D skin tissue model. The development of the 3D model is essential for testing finished products such as lotions and creams which cannot be applied directly to single layers of cells.

Cyprotex plc Announces Launch of KeratinoSens Service

Cyprotex PLC announced the launch of a new in vitro screening service for determining skin sensitisation using the KeratinoSens test method. In February 2014, EURL ECVAM (European Union Reference Laboratory for Alternatives to Animal Testing) published its recommendation on the KeratinoSens assay for use within an integrated strategy for skin sensitisation testing. The draft OECD (Organisation for Economic Co-operation and Development) test guidelines were released in May 2014 and Cyprotex has validated the assay based on these guidelines. Establishing in vitro alternatives to animal testing is a key goal of the regulatory authorities especially in the cosmetics and personal care markets where there has been a ban on animal testing in many countries for these products. The KeratinoSens test method extends Cyprotex's range of services in this segment. The Company now has a comprehensive panel of relevant in vitro methods for testing of skin and ocular irritation, skin corrosion, skin sensitisation, skin absorption and phototoxicity which are available to customers in the personal care/cosmetics, chemical and household products, and pharmaceutical industries. A skin sensitiser is a substance that leads to an allergic response following skin contact. This can manifest itself as allergic contact dermatitis which is a major occupational and environmental disease. Skin sensitisation is an important field of research for Cyprotex. As well as offering standard test methods such as the direct peptide reactivity assay (DPRA) and KeratinoSens, CeeTox (acquired by Cyprotex in January 2014) developed the SenCeeTox method which uses a multiparametric approach to evaluate skin sensitisation within a 3D skin model. Cyprotex continue to develop and improve this technology and it is a popular approach for screening finished products such as creams or lotions and insoluble chemicals.

Cyprotex plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Cyprotex plc reported unaudited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported revenue of £5,411,699 compared to £4,547,385 a year ago. Operating loss was £584,041 compared to operating profit of £316,667 a year ago. Loss before tax was £428,337 compared to profit before tax of £271,802 a year ago. Loss attributable to equity holders of the parent was of £404,724 or 0.18 pence per diluted share compared to profit attributable to equity holders of the parent of £298,272 or 0.13 pence per diluted share a year ago. Net cash used in operating activities was of £906,124 compared to net cash generated from operating activities of £587,631 a year ago. Purchase of property, plant and equipment was of £994,282 compared to £126,980 a year ago. Expenditure on intangible assets was £440,192. Underlying EBITDA was of £41,000 compared to £703,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRX:LN 42.00 GBp 0.00

CRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRX.
View Industry Companies
 

Industry Analysis

CRX

Industry Average

Valuation CRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYPROTEX PLC, please visit www.cyprotex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.